Association between steroid therapy and increased mortality in patients at risk for ARDS.

IF 1.2 Q4 CRITICAL CARE MEDICINE
Journal of Critical Care Medicine Pub Date : 2026-07-27 eCollection Date: 2026-07-01 DOI:10.62838/jccm-2026-0026
Sultan Almuntashiri, Andrew Bennett, Duo Zhang, Andrea Sikora, Aaron Chase
{"title":"Association between steroid therapy and increased mortality in patients at risk for ARDS.","authors":"Sultan Almuntashiri, Andrew Bennett, Duo Zhang, Andrea Sikora, Aaron Chase","doi":"10.62838/jccm-2026-0026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Corticosteroids are commonly used in critically ill patients with established risk factors for acute respiratory distress syndrome (ARDS), often for indications like sepsis or pneumonia, yet the choice of steroid and its impact on outcomes remain debated.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 160 ICU patients with documented clinical risk factors for ARDS at the time of ICU admission to evaluate the effect of corticosteroid therapy on hospital mortality. Clinical characteristics, treatment variables, and outcomes were compared between patients who received corticosteroids and those who did not. A subgroup exploratory analysis further compared outcomes between dexamethasone and hydrocortisone users. Logistic regression models were used to identify mortality predictors.</p><p><strong>Results: </strong>Of 160 patients, 91 (56.9%) received corticosteroids. Steroid-treated patients had higher Simplified Acute Physiology Score II (SAPS II) scores (54.4 vs. 48.0, p = 0.011), but no significant differences in age, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO<sub>2</sub>/FiO<sub>2</sub>), or mechanical ventilation use. Overall mortality was not significantly different between steroid and non-steroid users (42.9% vs. 33.3%, p = 0.221). Among steroid-treated patients, dexamethasone (n = 26) and hydrocortisone (n = 50) were the most frequently used agents. Mortality was significantly higher with hydrocortisone (58%) compared to dexamethasone (26.9%) (p = 0.010). In multivariate analysis, hydrocortisone use was associated with higher hospital mortality (adjusted OR = 4.41; 95% CI: 1.11-17.48; p = 0.035).</p><p><strong>Conclusion: </strong>Overall corticosteroid use was not associated with improved survival in patients with documented clinical risk factors for ARDS; however, in an exploratory analysis, hydrocortisone use was associated with higher hospital mortality than dexamethasone. Given the retrospective observational design and real-world factors influencing corticosteroid selection, including illness severity, these findings should be interpreted with caution and support the need for prospective studies to clarify these associations.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"12 3","pages":"418-425"},"PeriodicalIF":1.2000,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403008/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62838/jccm-2026-0026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Corticosteroids are commonly used in critically ill patients with established risk factors for acute respiratory distress syndrome (ARDS), often for indications like sepsis or pneumonia, yet the choice of steroid and its impact on outcomes remain debated.

Methods: We conducted a retrospective analysis of 160 ICU patients with documented clinical risk factors for ARDS at the time of ICU admission to evaluate the effect of corticosteroid therapy on hospital mortality. Clinical characteristics, treatment variables, and outcomes were compared between patients who received corticosteroids and those who did not. A subgroup exploratory analysis further compared outcomes between dexamethasone and hydrocortisone users. Logistic regression models were used to identify mortality predictors.

Results: Of 160 patients, 91 (56.9%) received corticosteroids. Steroid-treated patients had higher Simplified Acute Physiology Score II (SAPS II) scores (54.4 vs. 48.0, p = 0.011), but no significant differences in age, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2), or mechanical ventilation use. Overall mortality was not significantly different between steroid and non-steroid users (42.9% vs. 33.3%, p = 0.221). Among steroid-treated patients, dexamethasone (n = 26) and hydrocortisone (n = 50) were the most frequently used agents. Mortality was significantly higher with hydrocortisone (58%) compared to dexamethasone (26.9%) (p = 0.010). In multivariate analysis, hydrocortisone use was associated with higher hospital mortality (adjusted OR = 4.41; 95% CI: 1.11-17.48; p = 0.035).

Conclusion: Overall corticosteroid use was not associated with improved survival in patients with documented clinical risk factors for ARDS; however, in an exploratory analysis, hydrocortisone use was associated with higher hospital mortality than dexamethasone. Given the retrospective observational design and real-world factors influencing corticosteroid selection, including illness severity, these findings should be interpreted with caution and support the need for prospective studies to clarify these associations.

类固醇治疗与急性呼吸窘迫综合征高危患者死亡率增加之间的关系。
背景:皮质类固醇通常用于具有急性呼吸窘迫综合征(ARDS)危险因素的危重患者,通常用于败血症或肺炎等适应症,但类固醇的选择及其对预后的影响仍存在争议。方法:回顾性分析160例入院时伴有ARDS临床危险因素的ICU患者,评价皮质类固醇治疗对住院死亡率的影响。临床特征、治疗变量和结果比较了接受皮质类固醇治疗和未接受皮质类固醇治疗的患者。亚组探索性分析进一步比较了地塞米松和氢化可的松使用者之间的结果。使用逻辑回归模型确定死亡率预测因子。结果:160例患者中,91例(56.9%)接受了皮质激素治疗。类固醇治疗患者的简化急性生理评分II (SAPS II)得分较高(54.4比48.0,p = 0.011),但在年龄、动脉氧分压与吸入氧比(PaO2/FiO2)或机械通气使用方面无显著差异。类固醇和非类固醇使用者的总死亡率无显著差异(42.9%对33.3%,p = 0.221)。在类固醇治疗的患者中,地塞米松(n = 26)和氢化可的松(n = 50)是最常用的药物。氢化可的松组的死亡率(58%)明显高于地塞米松组(26.9%)(p = 0.010)。在多变量分析中,氢化可的松的使用与较高的住院死亡率相关(调整后OR = 4.41; 95% CI: 1.11-17.48; p = 0.035)。结论:在有ARDS临床危险因素的患者中,皮质类固醇的总体使用与生存率的提高无关;然而,在一项探索性分析中,氢化可的松的使用比地塞米松与更高的医院死亡率相关。考虑到回顾性观察设计和影响皮质类固醇选择的现实因素,包括疾病严重程度,这些发现应谨慎解释,并支持前瞻性研究以澄清这些关联的需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Critical Care Medicine
Journal of Critical Care Medicine CRITICAL CARE MEDICINE-
CiteScore
2.00
自引率
9.10%
发文量
21
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书